MedCity Influencers

Ray Elliott is leaving Boston Scientific (Best of MedCitizens)

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. This week’s life science current events include Ray Elliott and Boston Scientific’s new CEO, “Obamacare” and insurance agents, and Medtronic diabetes cuts.

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com.

Now here’s the best of what YOU had to say:

Boston Scientific CEO Ray Elliott retiring this year… but the new CEO will follow Elliott’s plans. “J. Raymond Elliott’s decision to step down as CEO of Boston Scientific began a little more than a month ago, when the company’s board asked him to document the accomplishments of his two-year tenure.”

The misguided war on insurance agents. “The Obama Administration has called small business ‘the backbone of our economy and the cornerstones of our communities.’ But the MLR rules undermine that claim. By driving scores of insurance agencies to the brink of bankruptcy — and killing small-business jobs in the process — the MLRs are making the health insurance marketplace even less accessible for everyone.”

Medtronic job cuts hit diabetes unit. “The Fridley, Minn.-based company has cut “hundreds” of employees in its diabetes unit, according to the ‘Diabetic Insider’ blog run by David Kliff, a prominent diabetes industry analyst.”

Is the pre-IDE process a waste of time? “An Investigational Device Exemption (IDE) approval is necessary before conducting FDA sanctioned medical device clinical trials. Companies often (around 200 times per year) utilize an informal pre-IDE process as a pre-cursor to the IDE application for the purpose of gaining insight from their FDA review team and presenting their product and testing or clinical plan. But, what seems like a no-brainer is not right for all projects, and a company needs to know to drop the informal interaction when it no longer serves its purpose.”

FDA regulators, meet the Heart Rhythm Society (please). “The FDA in 2009 did publish a draft guidance for the medical device industry in how it should present risk information. ’FDA believes it is critically important to disclose risk information in prescription drug and medical device promotion appropriately and effectively to healthcare professionals and consumers,’ it said. Alas, the guidance languishes, while the beat goes on at the Heart Rhythm Society.”

Chris Seper runs MedCityNews.com and contributes regularly to the site. He is the vice president of healthcare for Breaking Media, MedCity's corporate owners. Reach him at [email protected].

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.